Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising

1 Jul 2009

Abstract excerpt

Methotrexate (MTX) is a folate inhibitor that is used successfully in treating a great variety of malignancies and autoimmune diseases. However, there are certain drawbacks to its use, as a significant percentage of patients do not respond to the therapy or develop serious adverse effects. In the last ten years there has been a growing body of evidence pointing to the clinical significance of polymorphisms in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Autoimmune and Inflammatory Disorders Research
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19702537
DOI: 10.2174/138920009789375414

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is PromisingPMID 19702537Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Semantic proximity Read ↗

Methotrexate Pharmacogenetics in the Treatment of Rheumatoid ArthritisSemantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

GENETIC PREDICTORS OF TOXIC EFFECTS OF METHOTREXATE IN CANCER PATIENTS.Semantic proximity Read ↗

[Pharmacogenetics and pharmacogenomics of methotrexate. Current status and novel aspects].Semantic proximity Read ↗

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.Semantic proximity Read ↗

Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexateSemantic proximity Read ↗

Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.